Zoltán Szekanecz, Maya H Buch, Christina Charles-Schoeman, James Galloway, George A Karpouzas, Lars Erik Kristensen, Steven R Ytterberg, Attila Hamar, Roy Fleischmann
Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about their safety, particularly following the issuance of guidance by regulatory agencies advising caution in their use in certain patients. The registrational clinical trials and registry data of JAK inhibitors did not identify a difference in the risk of major adverse cardiovascular events (MACEs), venous thromboembolism, malignancies or infections (other than herpes zoster) with a JAK inhibitor versus a biologic DMARD...
February 2024: Nature Reviews. Rheumatology